We are live on ! Find out more
BCM

Burrage Capital Management Portfolio holdings

AUM $99.7M
1-Year Est. Return 66.05%
This Fund
S&P 500
This Quarter Est. Return
+0.22%
1 Year Est. Return
+66.05%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$127M
AUM Growth
-$16.2M
Cap. Flow
-$1.14M
Cap. Flow %
-0.9%
Top 10 Hldgs %
64.99%
Holding
29
New
3
Increased
12
Reduced
4
Closed
2

Top Buys

Rank Stock Value
1
ASMB icon
Assembly Biosciences
ASMB
+$4.2M
2
TCDA
Tricida, Inc. Common Stock
TCDA
+$2.75M
3
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$1.53M
4
EPZM
Epizyme, Inc
EPZM
+$1.49M
5
CALT
Calliditas Therapeutics AB American Depositary Shares
CALT
+$257K

Top Sells

Rank Stock Value
1
TECX
Tectonic Therapeutic
TECX
+$3.94M
2
ADVM
Adverum Biotechnologies
ADVM
+$3.26M
3
GTHX
G1 Therapeutics, Inc. Common Stock
GTHX
+$2.4M
4
KRRO icon
Korro Bio
KRRO
+$1.5M
5
ZGNX
Zogenix, Inc.
ZGNX
+$755K

Sector Composition

Rank Sector Weight
1 Healthcare 90.96%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EPZM
1
DELISTED
Epizyme, Inc
EPZM
$12M 9.44%
1,002,528
+111,251
+12% +$1.49M
AIMT
2
DELISTED
Aimmune Therapeutics
AIMT
$11.5M 9.04%
332,546
– –
LITS
3
Lite Strategy Inc
LITS
$33.6M
$9.48M 7.49%
151,952
+1,894
+1% +$114K
ISEE
4
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$8.44M 6.66%
1,495,515
+18,644
+1% +$88.9K
PTCT icon
5
PTC Therapeutics
PTCT
$6.52B
$8.11M 6.4%
173,545
-5,841
-3% -$288K
KIDS icon
6
OrthoPediatrics
KIDS
$493M
$7.88M 6.22%
171,607
+2,139
+1% +$99.2K
NEO icon
7
NeoGenomics
NEO
$1.9B
$7.11M 5.61%
192,671
+2,466
+1% +$91.7K
TPTX
8
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$6.82M 5.39%
78,118
+946
+1% +$65.9K
CYTK icon
9
Cytokinetics
CYTK
$10.9B
$5.73M 4.53%
264,859
+3,368
+1% +$78.8K
AUPH icon
10
Aurinia Pharmaceuticals
AUPH
$2.05B
$5.34M 4.21%
362,383
+105,945
+41% +$1.53M
INSM icon
11
Insmed
INSM
$23.5B
$5.32M 4.2%
165,400
– –
ANAB icon
12
AnaptysBio
ANAB
$1.72B
$4.88M 3.85%
330,549
+2,435
+0.7% +$43.9K
YMAB
13
DELISTED
Y-mAbs Therapeutics
YMAB
$4.72M 3.73%
123,025
– –
ADCT icon
14
ADC Therapeutics
ADCT
$172M
$4.45M 3.51%
134,912
– –
CRNX icon
15
Crinetics Pharmaceuticals
CRNX
$8.88B
$3.78M 2.98%
241,278
+4,884
+2% +$74.7K
ASMB icon
16
Assembly Biosciences
ASMB
$531M
$3.29M 2.6%
+16,667
New +$4.2M
RGNX icon
17
Regenxbio
RGNX
$511M
$3.2M 2.53%
116,405
+1,405
+1% +$45.8K
GTHX
18
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$2.64M 2.08%
228,597
-145,279
-39% -$2.4M
KRRO icon
19
Korro Bio
KRRO
$177M
$2.58M 2.03%
2,683
-1,395
-34% -$1.5M
APLS
20
DELISTED
Apellis Pharmaceuticals
APLS
$2.32M 1.83%
76,804
+2,352
+3% +$70.3K
FULC icon
21
Fulcrum Therapeutics
FULC
$243M
$2.31M 1.83%
291,645
– –
TCDA
22
DELISTED
Tricida, Inc. Common Stock
TCDA
$1.71M 1.35%
+188,182
New +$2.75M
MRUS
23
DELISTED
Merus
MRUS
$1.68M 1.33%
140,176
– –
ZGNX
24
DELISTED
Zogenix, Inc.
ZGNX
$703K 0.56%
39,189
-30,811
-44% -$755K
KDNY
25
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$330K 0.26%
27,180
– –
1
2

Similar funds

WCM
Weld Capital Management New York $98.8M AUM 52.83% 1-Year Est. Return
CCM
Coe Capital Management Highland Park, Illinois $106M AUM 53.24% 1-Year Est. Return
RGM
ROAM Global Management New York $117M AUM
TCM
Taal Capital Management Boston, Massachusetts $122M AUM 50.45% 1-Year Est. Return
RC
Regents Capital Hong Kong $76.8M AUM
AC
Aperimus Capital Marina Del Rey, California $62.2M AUM 47.35% 1-Year Est. Return
QVT
Quantitative Value Technologies Overland Park, Kansas $60.7M AUM
WFWM
Wechter Feldman Wealth Management Parsippany, New Jersey $143M AUM 25.17% 1-Year Est. Return

Burrage Capital Management's Q3 2020 Portfolio in Review

As of Q3 2020, Burrage Capital Management held 29 positions worth $127M, down 11% from $143M the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Burrage Capital Management's Q3 2020 filing shows 3 new, 12 increased, 4 reduced and 2 closed positions. Its largest new stake was Assembly Biosciences: 16,667 shares worth $3.29M. The largest sale was Tectonic Therapeutic, an estimated $3.94M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 96% a quarter earlier.

  • Burrage Capital Management's largest Q3 2020 buy was Assembly Biosciences: 16,667 shares worth $3.29M.
  • Burrage Capital Management added most to Aurinia Pharmaceuticals in Q3 2020, an estimated $1.53M increase.
  • Burrage Capital Management's biggest Q3 2020 reduction was G1 Therapeutics, Inc. Common Stock, cutting an estimated $2.4M.
  • Burrage Capital Management fully exited Tectonic Therapeutic in Q3 2020, selling an estimated $3.94M.
  • Burrage Capital Management's ten largest holdings make up 65% of its $127M portfolio in Q3 2020.
  • Burrage Capital Management opened 3 new positions and closed 2 in Q3 2020.
  • Burrage Capital Management's portfolio value fell 11% quarter-over-quarter to $127M.

Based on Burrage Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.